Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORRECT: Regorafenib in Metastatic Colorectal Cancer
NCT01103323Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Regorafenib + BSC with Placebo + BSC (2 arms). Primary endpoint: Overall Survival at 14 months. Started Apr 2010; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01103323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103323.